Skip to main navigation Skip to search Skip to main content

A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease.

Translated title of the contribution: A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease.
  • W. Reinisch
  • , D.W. Hommes
  • , G. van Assche
  • , J.F. Colombel
  • , J.P. Gendre
  • , B. Oldenburg
  • , A. Teml
  • , K. Geboes
  • , H. Ding
  • , L. Zhang
  • , M. Tang
  • , M. Cheng
  • , S.J.H. van Deventer
  • , P. Rutgeerts
  • , T. Pearce

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionA dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease.
Original languageUndefined/Unknown
Pages (from-to)1138-1144
Number of pages7
JournalGut
Volume55
Publication statusPublished - 2006

Cite this